stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Revenue growth
Veracyte, Inc.'s revenue growth over the twelve months to 30 September 2026 was 17.5%, up 1.5 percentage points from fiscal 2025 (16.0%). Over the past ten years it has ranged from −2.40% (fiscal 2020) to 86.9% (fiscal 2021); the current reading is higher than 27% of that period. That is above the Diagnostics & Research industry median of 8.99% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 16.0% | (7.45) |
| FY2024 | 23.5% | 1.70 |
| FY2023 | 21.8% | (13.33) |
| FY2022 | 35.1% | (51.76) |
| FY2021 | 86.9% | 89.25 |
| FY2020 | −2.40% | (33.22) |
| FY2019 | 30.8% | 2.95 |
| FY2018 | 27.9% | 17.32 |
| FY2017 | 10.6% | (20.93) |
| FY2016 | 31.5% | 1.86 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 15.1% | (0.41) |
| Jun 2026 | 15.5% | (6.00) |
| Mar 2026 | 21.5% | 2.94 |
| Dec 2025 | 18.6% | 4.73 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BLLN BillionToOne, Inc. compare | 76.5% |
| CDNA CareDx, Inc. compare | 38.9% |
| WGS GeneDx Holdings Corp. compare | 25.4% |
| RDNT RadNet, Inc. compare | 18.9% |
| ADPT Adaptive Biotechnologies Corporation compare | 17.9% |
| VCYT Veracyte, Inc. | 17.5% |
| GRAL GRAIL, Inc. compare | 17.5% |
| NEO NeoGenomics, Inc. compare | 11.1% |
| SHC Sotera Health Company compare | 6.90% |
| Diagnostics & Research industry median | 8.99% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement